Catalyst Pharmaceuticals/$CPRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
Ticker
$CPRX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
181
Website
CPRX Metrics
BasicAdvanced
$2.6B
13.60
$1.57
0.66
-
Price and volume
Market cap
$2.6B
Beta
0.66
52-week high
$26.58
52-week low
$15.34
Average daily volume
1.3M
Financial strength
Current ratio
6.142
Quick ratio
5.848
Long term debt to equity
0.338
Total debt to equity
0.389
Profitability
EBITDA (TTM)
269.169
Gross margin (TTM)
83.50%
Net profit margin (TTM)
36.91%
Operating margin (TTM)
43.27%
Effective tax rate (TTM)
23.64%
Revenue per employee (TTM)
$2,950,000
Management effectiveness
Return on assets (TTM)
18.59%
Return on equity (TTM)
29.11%
Valuation
Price to earnings (TTM)
13.599
Price to revenue (TTM)
4.772
Price to book
3.28
Price to tangible book (TTM)
4.02
Price to free cash flow (TTM)
9.536
Free cash flow yield (TTM)
10.49%
Free cash flow per share (TTM)
2.237
Growth
Revenue change (TTM)
29.97%
Earnings per share change (TTM)
178.13%
3-year revenue growth (CAGR)
51.51%
3-year earnings per share growth (CAGR)
55.17%
10-year earnings per share growth (CAGR)
20.36%
What the Analysts think about CPRX
Analyst ratings (Buy, Hold, Sell) for Catalyst Pharmaceuticals stock.
Bulls say / Bears say
Catalyst Pharmaceuticals achieved record total revenues of $398.2 million in 2023, marking an 85.9% increase compared to 2022, demonstrating strong financial growth. (catalystpharma.com)
The FDA approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy in late 2023 expands Catalyst's product portfolio and opens new revenue streams. (catalystpharma.com)
Catalyst's acquisition of U.S. rights for Fycompa (perampanel) CIII from Eisai Co., Ltd. in 2023 diversifies its portfolio with a commercial-stage epilepsy asset, contributing to revenue growth. (nasdaq.com)
In 2023, Catalyst reported a GAAP net income of $71.4 million, a 14% decrease from 2022, indicating potential profitability challenges. (catalystpharma.com)
The company's cash and cash equivalents decreased by 53.9% from $298.4 million in 2022 to $137.6 million in 2023, which may impact its financial flexibility. (catalystpharma.com)
Catalyst's operating expenses increased significantly in 2023, with selling, general, and administrative expenses rising by 120% year-over-year, potentially affecting profit margins. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
CPRX Financial Performance
Revenues and expenses
CPRX Earnings Performance
Company profitability
CPRX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Catalyst Pharmaceuticals stock?
Catalyst Pharmaceuticals (CPRX) has a market cap of $2.6B as of August 01, 2025.
What is the P/E ratio for Catalyst Pharmaceuticals stock?
The price to earnings (P/E) ratio for Catalyst Pharmaceuticals (CPRX) stock is 13.6 as of August 01, 2025.
Does Catalyst Pharmaceuticals stock pay dividends?
No, Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Catalyst Pharmaceuticals dividend payment date?
Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals (CPRX) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.